Therapy of Parkinson’s Disease

1. Carlsson, Cotzias, and the Birth of L-DOPA

In 1957 the Swedish pharmacologist Arvid Carlsson showed that reserpine — an antihypertensive that depletes monoamines — produced akinesia and rigidity in rabbits, and that oral L-DOPA reversed it (Carlsson, Lindqvist, Magnusson, Nature 1957). He went on to demonstrate that dopamine — previously thought to be merely a precursor of noradrenaline — was concentrated in the basal ganglia and was itself a neurotransmitter (Carlsson et al., 1958). For this work he shared the 2000 Nobel Prize in Physiology or Medicine.

The clinical translation was attempted immediately by Birkmayer and Hornykiewicz in Vienna (1961), who infused intravenous L-DOPA into PD patients and observed dramatic but transient motor benefit. The results were initially controversial. In 1967 George Cotzias at Brookhaven National Laboratory (NEJM 1967, 1969) showed that high-dose oral L-DOPA, titrated slowly to several grams per day, produced sustained dramatic improvement in PD — the result that defined modern Parkinson’s therapy.

The early years saw severe nausea, vomiting and orthostatic hypotension at effective doses, because most of the L-DOPA was decarboxylated to dopamine outside the brain. The 1970s brought peripheral AADC inhibitors(carbidopa, benserazide), which prevented this peripheral conversion and let the effective brain dose drop ~75% with a vastly improved tolerability profile. Sinemet (carbidopa/levodopa) reached the US market in 1975 and remains the dominant formulation.

2. Levodopa & Carbidopa Pharmacology

L-DOPA (levodopa) is the prodrug; dopamine itself does not cross the blood-brain barrier. L-DOPA does, via the large neutral amino-acid transporter (LAT1). Once central, it is decarboxylated by AADC in surviving SNc terminals (and in serotonergic raphe terminals, which becomes important when SNc terminals are depleted) to dopamine.

• Bioavailability ~30%; first-pass metabolism by gut and liver AADC.
• Plasma t½ ~1.5 h with carbidopa; this short half-life drives motor fluctuations once buffering is lost.
• Tmax ~30–90 min on empty stomach; delayed by dietary protein (LAT1 competition with large neutral amino acids).
• Carbidopa 25 mg per dose is sufficient to saturate peripheral AADC; doses are usually 25/100 mg (carbidopa/levodopa) three to four times daily as a starting regimen.
• Formulations — immediate-release (Sinemet), controlled-release (Sinemet CR), extended-release capsule (Rytary, IPX066, three pellet types in one), inhaled (Inbrija, for OFF rescue), intestinal gel (Duopa/Duodopa), and the new subcutaneous foslevodopa-foscarbidopa (Vyalev/Produodopa, 2024).

Single-dose plasma levels follow standard absorption-elimination kinetics:

\[ C(t) \;=\; \frac{F\,D}{V_d}\;\frac{k_a}{k_a - k_e}\;\bigl(e^{-k_e t} - e^{-k_a t}\bigr) \]

where F is bioavailability, D is dose, V_d volume of distribution, k_a the absorption rate constant, and k_e the elimination rate constant. For oral levodopa+carbidopa, the steep peak-and-trough profile underlies the “wearing-off” phenomenon as nigral buffering capacity is lost.

3. LEDD — The Levodopa-Equivalent Daily Dose

When patients are on cocktails of dopaminergic drugs, the levodopa-equivalent daily dose (LEDD)standardises total dopaminergic burden into a single number. The conversion factors (Tomlinson et al., Mov Disord 2010; updated thereafter) are:

\[ \text{LEDD} \;=\; \sum_i (D_i \cdot f_i) \quad \text{where } f_i \text{ is the levodopa-equivalence factor for drug } i \]

Worked example: a patient on Sinemet 25/100 four times daily + entacapone 200 mg with each dose + pramipexole ER 1.5 mg + rasagiline 1 mg has LEDD = (4 × 100 × 1.33) + (1.5 × 100) + (1 × 100) = 532 + 150 + 100 = 782 mg LEDD. Most patients with advanced PD ultimately reach 800–1500 mg LEDD; a young patient first starting therapy is typically <500 mg.

4. Dopamine Agonists

Direct postsynaptic D2/D3 agonists bypass the dying SNc terminal entirely. They are less effective than levodopa for motor symptoms but offer:

• Long half-life ⇒ smoother dopaminergic stimulation, fewer motor fluctuations and dyskinesias compared with peak-and-trough levodopa.
• Antidepressant effect (especially pramipexole; via D3 receptor activity).
• Useful in monotherapy in young patients hesitant about long-term levodopa fluctuations — though the PD-MED data have moderated this advantage.

Modern non-ergot agonists (the ergots, bromocriptine and pergolide, are obsolete due to fibrotic valvulopathy):

Side-effect profile of agonists differs systematically from levodopa: more sleep attacks, more impulse-control disorders, more orthostatic hypotension, more peripheral oedema, more confusion in the elderly. The DOMINION study (Weintraub et al., Arch Neurol 2010) found ICD prevalence ~17% on agonists vs ~7% on levodopa — a class-effect related to D3 receptor activity in mesolimbic circuits.

5. MAO-B Inhibitors

Monoamine oxidase B is the predominant brain isoform; selective MAO-B inhibition prolongs synaptic dopamine without the dietary tyramine concerns of non-selective MAO inhibition (no “cheese reaction” at therapeutic doses).

• Selegiline (deprenyl) — the original; 5–10 mg/day. Active metabolites include amphetamine; can cause insomnia. The DATATOP trial (NEJM 1989) suggested neuroprotection but was confounded by symptomatic effect. Orally disintegrating Zelapar avoids first-pass amphetamine metabolite.
• Rasagiline — 1 mg/day; non-amphetamine metabolite. ADAGIO trial (Olanow et al., NEJM 2009) showed delayed-start benefit with 1 mg but not 2 mg — an inconsistent result that made it unconvincing as a disease-modifier despite FDA-acknowledged efficacy as symptomatic and adjunct therapy.
• Safinamide — 50–100 mg/day; reversible, dual MAO-B and Na⁺-channel/glutamate modulator. Approved as adjunct for fluctuations in advanced PD (SETTLE trial, Schapira et al., JAMA Neurol 2017).

Modest symptomatic benefit (~3 UPDRS-III points) when used as monotherapy; useful add-on for early wearing-off. Avoid in combination with serotonergic agents (rare serotonin syndrome) and meperidine.

6. COMT Inhibitors

Catechol-O-methyltransferase (COMT) is the alternative pathway for L-DOPA metabolism (to 3-O-methyldopa, 3-OMD). Peripheral COMT inhibition prolongs levodopa half-life and increases its AUC by ~30–50%, smoothing motor response. Always given with levodopa, never as monotherapy.

• Entacapone — 200 mg with each levodopa dose. Co-formulated with carbidopa/levodopa as Stalevo. Brick-coloured urine; diarrhoea. The dominant COMT-i for two decades.
• Tolcapone — 100–200 mg three times daily; rare fulminant hepatotoxicity restricts use; LFT monitoring mandatory.
• Opicapone — 50 mg once daily; long-acting; BIPARK-1/2 trials. Increasingly preferred in advanced PD wearing-off.

7. Amantadine and Anticholinergics

Amantadine is an NMDA receptor antagonist (and weak dopamine releaser) originally developed as an anti-influenza drug, found serendipitously to improve PD in 1969 (Schwab et al., JAMA). Two clinical roles:

• Adjunct symptomatic therapy — modest benefit on tremor and bradykinesia in early PD; 100 mg twice or three times daily.
• Treatment of L-DOPA-induced dyskinesias — the unique anti-dyskinetic agent; 200–400 mg/day; the extended-release formulation Gocovri received FDA approval (2017) specifically for this. Mechanism: NMDA antagonism rebalances overactive cortico-striatal glutamatergic drive.

Side effects: livedo reticularis, ankle oedema, hallucinations and confusion in the elderly, cognitive impairment.

Anticholinergics (trihexyphenidyl, benztropine) are the oldest PD therapy — Charcot used hyoscyamus tincture in the 1880s. Useful only for tremor; modest at best. Strong anticholinergic burden — cognitive impairment, urinary retention, dry mouth, confusion — means they are now reserved for younger patients with severe tremor not responding to dopaminergics, and absolutely avoided in the elderly or in any patient with even subtle cognitive decline. The Beers criteria flag them prominently.

8. Motor Fluctuations and Dyskinesias

The defining management problem of established PD: motor complications appear in ~50% of patients within 5 years of starting levodopa, ~80% by 10 years (Ahlskog and Muenter, Mov Disord 2001). They reflect the loss of nigral buffering capacity: with surviving terminals <30% of normal, the striatum can no longer smooth the peaks and troughs of oral L-DOPA absorption.

Motor fluctuations

• Wearing-off — predictable return of parkinsonism before the next dose. Manage with shorter intervals, controlled-release formulations, COMT inhibitors, MAO-B inhibitors, or apomorphine rescue.
• Delayed-on / no-on — failure of an oral dose, often dietary protein interference. Manage by taking levodopa 30 min before meals, or switching to inhaled levodopa (Inbrija).
• Random / unpredictable on-off — the most disabling form; suggests advanced disease and need for continuous dopaminergic delivery.
• Early-morning OFF — manage with bedtime CR levodopa, evening agonist, or SC apomorphine first thing.

Dyskinesias

• Peak-dose chorea — the commonest form; choreiform involuntary movements at peak L-DOPA. Manage with smaller, more frequent doses; add amantadine; consider DBS in disabling cases.
• Diphasic — dyskinesia at the rising and falling edges of L-DOPA, with parkinsonism between. Harder to manage; often needs continuous delivery.
• OFF dystonia — painful sustained postures (often early-morning foot dystonia); responds to night-time CR levodopa or first-thing apomorphine.

The mechanistic story: pulsatile dopamine receptor stimulation (especially D1) produces aberrant LTP/LTD-like plasticity in striatal MSNs, with loss of the normal ability to scale firing in response to dopamine signal — the striatal-priming hypothesis. Continuous dopaminergic stimulation (CDS) — via transdermal rotigotine patch, intestinal gel, subcutaneous foslevodopa pump — partly reverses this priming.

9. Impulse-Control Disorders & Other Behavioural Complications

Impulse-control disorders (ICDs)— pathological gambling, hypersexuality, compulsive shopping, binge eating — affect ~17% of patients on dopamine agonists vs ~7% on levodopa (Weintraub et al., Arch Neurol 2010). Risk factors include male sex, young onset, family or personal history of addiction, and depression. Mechanism: D3 receptor stimulation in mesolimbic and ventral-striatal reward circuitry.

• Always screen at every visit (QUIP-RS or direct questioning of patient + spouse).
• First-line management: reduce agonist dose; switch to levodopa if needed.
• Agonist withdrawal can produce dopamine agonist withdrawal syndrome (DAWS) — anxiety, panic, dysphoria, fatigue; taper slowly.
• Naltrexone has shown benefit in small trials.

Dopamine dysregulation syndrome (DDS): compulsive overuse of dopaminergic medication, often with associated punding (purposeless stereotyped activity). Younger, male, severe disease.

PD psychosis: visual hallucinations, delusions; up to 50% in advanced PD. First step: identify and reduce/eliminate culprit drugs (anticholinergics first, then amantadine, then agonists, then COMT-i, then MAO-B-i, then levodopa). If antipsychotic needed, pimavanserin (5-HT2A inverse agonist; FDA-approved 2016) is preferred; quetiapine and clozapine acceptable (clozapine is most efficacious but requires WBC monitoring). Avoidrisperidone, olanzapine, haloperidol, all of which dramatically worsen PD motor function.

10. Deep Brain Stimulation

The most successful surgical therapy in modern neurology. Alim-Louis Benabid at Grenoble showed in 1987 that high-frequency stimulation of the ventral intermediate (VIM) thalamus suppressed tremor (Benabid et al., Lancet 1987), and in 1994 that subthalamic stimulation (STN-DBS) reversed all cardinal motor features (Limousin et al., Lancet 1995). Benabid shared the 2014 Lasker Award.

Mechanism remains debated — high-frequency (~130–180 Hz) stimulation acts as a functional lesion via several non-exclusive routes: depolarisation block of cell bodies, antidromic activation of cortico-STN axons, regularisation of pathological β-band oscillations, modulation of striatal circuit dynamics. Whatever the mechanism, the effect on motor symptoms is profound.

Targets

Landmark trials

• Deuschl et al., NEJM 2006 — STN-DBS vs best medical therapy; substantial improvement in quality of life and motor function.
• PALLAS / Follett et al., NEJM 2010 — STN vs GPi: similar motor benefit; STN allows greater LEDD reduction; GPi spares cognition/mood. Choice of target individualised.
• EARLYSTIM / Schuepbach et al., NEJM 2013 — STN-DBS in earlier disease (mean disease duration 7.5 yr, age <60, early fluctuations) significantly outperformed best medical therapy on quality of life. Pushed surgery earlier in the trajectory.
• Williams et al., Lancet Neurol 2010 — PD-SURG; STN-DBS vs medical therapy; ~5-year quality-of-life advantage.

Patient selection (CAPSIT-PD framework)

• Idiopathic PD with clear levodopa response (>30% UPDRS-III improvement on best ON).
• Disabling motor fluctuations or dyskinesias despite optimised oral therapy.
• No significant cognitive impairment (MoCA >20–24 typically required) and no active psychosis.
• Age historically <70–75; with EARLYSTIM data, increasingly offered earlier and to fitter older patients.
• No severe medical comorbidity contraindicating surgery.

Modern devices include directional leads (Boston Vercise Cartesia, Medtronic SenSight), allowing current steering to optimise benefit and minimise side effects, and closed-loop adaptive DBS systems (Medtronic Percept, NeuroPace) that titrate stimulation to detected β oscillations — the next frontier.

11. Levodopa-Carbidopa Intestinal Gel and Continuous Subcutaneous Therapy

For advanced PD with disabling fluctuations where DBS is contraindicated or unwanted, continuous dopaminergic deliveryvia direct duodenal infusion mimics the smooth dopaminergic stimulation that the dying SNc can no longer provide:

• Levodopa-carbidopa intestinal gel (LCIG / Duopa / Duodopa) — PEG-J tube to jejunum + Aprila pump delivering levodopa-carbidopa gel over 16 waking hours. The DIREQT/DUOGLOBE trials and Olanow et al. Lancet Neurol 2014 showed substantial reduction in OFF time. Tube complications (dislodgement, infection, peritonitis) and B12/peripheral neuropathy from levodopa-induced homocysteinaemia are limitations.
• LECIG (levodopa-entacapone-carbidopa gel) — a more concentrated formulation (Lecigon) approved 2019.
• Foslevodopa-foscarbidopa SC (Vyalev/Produodopa, 2024) — subcutaneous 24-h infusion of soluble pro-drugs; non-invasive equivalent of LCIG.
• Apomorphine SC pump — D1/D2 agonist; continuous SC infusion 12–16 h/day; alternative for fluctuators not suited to DBS or LCIG. Skin nodules; nausea (pretreat with domperidone).

12. MRI-Guided Focused Ultrasound (MRgFUS)

Transcranial MRgFUS uses 1024-element phased-array ultrasound transducers to deliver focused acoustic energy through the intact skull, raising temperature to ~58°C in a millimetre-scale focal spot and producing a precision lesion — an incisionless thalamotomy or pallidotomy. No hardware, no incision, no infection risk. Real-time MRI thermometry guides the ablation.

• VIM thalamotomy — FDA-approved 2018 for medication-refractory tremor (essential tremor) and 2018 for tremor-dominant PD. Unilateral; ~75% sustained tremor reduction.
• GPi pallidotomy — FDA-approved 2021 for advanced PD with motor complications (Bond et al., NEJM 2017; Krishna et al., NEJM 2023; ~70% improvement in OFF-medication MDS-UPDRS-III).
• STN ablation — investigational; promising but more challenging anatomically.
• Currently unilateral only — bilateral lesion of motor circuits carries unacceptable side-effect risk.

FUS is particularly valuable for patients ineligible for or wishing to avoid DBS hardware, those with bleeding risk, and those with strong tremor as the dominant feature. The frontier in PD includes blood-brain-barrier opening for drug delivery (microbubble-assisted FUS), and is reviewed in Part VIII.